Several ADCs have been designed and used for clinical use in hematologic malignancies and their targets include CD22,187–193 CD30,181,194–197 CD33,198–202 CD19,203–208 CD79,191,209,210 BCMA,211,212 CD37,213–215 CD138,216 CD56,217 CD74,218 GPRC5D,219 CD123,220 and CD25,221 (Table 1). This evidence concerns the gene CD33 and hematologic disorder.